{"paper_id":"b1260367-2b90-47de-bd64-53e2ae409895","body_text":"Abstract\nPurpose of Review\nThis review aims to provide a comprehensive summary of the literature regarding the use of uterine artery embolization (UAE) in the treatment of pure adenomyosis and to document indications, results and complications for symptomatic patients who have failed conservative treatment and wish to avoid hysterectomy.\nRecent Findings\nThere is growing evidence to support UAE as a safe and successful treatment for the treatment of symptomatic pure adenomyosis.\nSummary\nPure adenomyosis has historically been treated with conservative pharmacological treatments including non-steroidal anti-inflammatories, hormonal contraceptive medications, and intrauterine devices. When such treatments have failed, hysterectomy has served as a definitive treatment for patients with symptomatic adenomyosis. However, the use of UAE to treat symptomatic adenomyosis has gained attraction in recent years as a less invasive and uterine sparing procedure, which may prove to be a suitable alternative for patients wishing to avoid hysterectomy. With the low rate of major complications in accordance with the Society of Interventional Radiology (SIR) classification and good success rates, UAE should be proposed as an alternative for patients who have failed medical therapy.\nSimilar content being viewed by others\nReferences\nPapers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance\nBird CC, McElin TW, Manalo-Estrella P. The elusive adenomyosis of the uterus-revisited. Am J Obstet Gynecol. 1972;112:583–93.\nChen J, Porter AE, Kho KA. Current and future surgical and interventional management options for adenomyosis. Semin Reprod Med. 2020;38:157–67.\nKho KA, Chen JS, Halvorson LM. Diagnosis, evaluation, and treatment of adenomyosis. JAMA. 2021;326:177.\nTaran F, Stewart E, Brucker S. Adenomyosis: Epidemiology, risk factors, clinical phenotype and surgical and interventional alternatives to hysterectomy. Geburtshilfe Frauenheilkd. 2013;73:924–31.\nUpson K, Missmer SA. Epidemiology of adenomyosis. Semin Reprod Med. 2020;38:089–107.\nYu O, Schulze-Rath R, Grafton J, Hansen K, Scholes D, Reed SD. Adenomyosis incidence, prevalence and treatment: United States population-based study 2006–2015. Am J Obstet Gynecol. 2020. https://doi.org/10.1016/j.ajog.2020.01.016.\nRathinam KK, Abraham JJ, Heema Preethy S, Shevaani SA, Sen M, George M, Priyadharshini A. Evaluation of pharmacological interventions in the management of Adenomyosis: a systematic review. Eur J Clin Pharmacol. 2022;78:531–45.\n• Oliveira MA, Brollo LC, Soares T, Pereira TD, de Souza RJ. Surgical treatment of adenomyosis. Current Obstetrics and Gynecology Reports. 2022;11:180–5. This research article provides a comprehensive list of the current surgical options for the treatment of adenomyosis, including uterine artery embolization.\nKhalilzadeh O, Baerlocher MO, Shyn PB, et al. Proposal of a new adverse event classification by the Society of Interventional Radiology Standards of Practice Committee. J Vasc Interv Radiol. 2017. https://doi.org/10.1016/j.jvir.2017.06.019.\nSiskin GP, Tublin ME, Stainken BF, Dowling K, Dolen EG. Uterine artery embolization for the treatment of adenomyosis. Am J Roentgenol. 2001;177:297–302.\nWang S, Meng X, Dong Y. The evaluation of uterine artery embolization as a nonsurgical treatment option for adenomyosis. Int J Gynecol Obstet. 2015;133:202–5.\nFroeling V, Scheurig-Muenkler C, Hamm B, Kroencke TJ. Uterine artery embolization to treat uterine adenomyosis with or without uterine leiomyomata: Results of symptom control and health-related quality of life 40 months after treatment. Cardiovasc Intervent Radiol. 2011;35:523–9.\nTellum T, Nygaard S, Lieng M. Noninvasive diagnosis of adenomyosis: a structured review and meta-analysis of diagnostic accuracy in imaging. J Minim Invasive Gynecol. 2020. https://doi.org/10.1016/j.jmig.2019.11.001.\nCunningham RK, Horrow MM, Smith RJ, Springer J. Adenomyosis: a sonographic diagnosis. Radiographics. 2018;38:1576–89.\nBazot M, Cortez A, Darai E, Rouger J, Chopier J, Antoine J-M, Uzan S. Ultrasonography compared with magnetic resonance imaging for the diagnosis of adenomyosis: correlation with histopathology. Hum Reprod. 2001;16:2427–33.\n•• Zhang M, Bazot M, Tsatoumas M, Munro MG, Reinhold C. MRI of adenomyosis: Where are we today? Can Assoc Radiol J. 2022;74:58–68. This research article supports MRI as an excellent non-invasive tool that can facilitate the detection and definition of adenomyosis features with a potential to stratify patient management.\nBazot M, Daraï E. Role of transvaginal sonography and Magnetic Resonance Imaging in the diagnosis of uterine adenomyosis. Fertil Steril. 2018;109:389–97.\nRees CO, Nederend J, Mischi M, Vliet HA, Schoot BC. Objective measures of adenomyosis on MRI and their diagnostic accuracy—a systematic review & meta-analysis. Acta Obstet Gynecol Scand. 2021;100:1377–91.\nde Bruijn AM, Smink M, Lohle PNM, Huirne JAF, Twisk JWR, Wong C, Schoonmade L, Hehenkamp WJK. Uterine artery embolization for the treatment of adenomyosis: a systematic review and meta-analysis. J Vasc Interv Radiol. 2017. https://doi.org/10.1016/j.jvir.2017.07.034.\nPopovic M, Puchner S, Berzaczy D, Lammer J, Bucek RA. Uterine artery embolization for the treatment of adenomyosis: a Review. J Vasc Interv Radiol. 2011;22:901–9.\nJha RC, Takahama J, Imaoka I, Korangy SJ, Spies JB, Cooper C, Ascher SM. adenomyosis: MRI of the uterus treated with uterine artery embolization. Am J Roentgenol. 2003;181:851–6.\nKim MD, Kim S, Kim NK, Lee MH, Ahn EH, Kim HJ, Cho JH, Cha SH. Long-term results of uterine artery embolization for symptomatic adenomyosis. Am J Roentgenol. 2007;188:176–81.\nSmeets AJ, Nijenhuis RJ, Boekkooi PF, Vervest HA, van Rooij WJ, Lohle PN. Long-term follow-up of uterine artery embolization for symptomatic adenomyosis. Cardiovasc Intervent Radiol. 2011;35:815–9.\nNijenhuis RJ, Smeets AJ, Morpurgo M, Boekkooi PF, Reuwer PJ, Smink M, van Rooij WJ, Lohle PN. Uterine artery embolisation for symptomatic adenomyosis with Polyzene F-coated hydrogel microspheres: Three-year clinical follow-up using UFS–Qol Questionnaire. Cardiovasc Intervent Radiol. 2014;38:65–71.\nBae SH, Kim MD, Kim GM, Lee SJ, Park SI, Won JY, Lee DY. Uterine artery embolization for adenomyosis: Percentage of necrosis predicts midterm clinical recurrence. J Vasc Interv Radiol. 2015. https://doi.org/10.1016/j.jvir.2015.04.026.\nKim MD, Kim YM, Kim HC, Cho JH, Kang HG, Lee C, Kim HJ, Lee JT. Uterine artery embolization for symptomatic adenomyosis: A new technical development of the 1-2-3 protocol and predictive factors of MR imaging affecting outcomes. J Vasc Interv Radiol. 2011;22:497–502.\nPelage J-P, Jacob D, Fazel A, Namur J, Laurent A, Rymer R, Le Dref O. Midterm results of uterine artery embolization for symptomatic adenomyosis: Initial experience. Radiology. 2005;234:948–53.\nWang Y, Lyu W, Xu W, Yu Y. Asherman syndrome in adenomyosis treated with uterine artery embolization: Incidence predictive factors. Radiol Med (Torino). 2020;125:437–43.\n•• Yuan K, Zhang JL, Yan JY, Yuan B, Fu JX, Wang Y, Sun XD, Guan Y, Duan F, Wang MQ. Uterine artery embolization with small-sized particles for the treatment of symptomatic adenomyosis: A 42-month clinical follow-up. Int J Gen Med. 2021;14:3575–81. This study demonstrates the long-term effectiveness and safety of uterine artery embolization utilizing small particles for the treatment of adenomyosis.\nLiang E, Brown B, Kirsop R, Stewart P, Stuart A. Efficacy of uterine artery embolisation for treatment of symptomatic fibroids and adenomyosis - an interim report on an Australian experience. Aust N Z J Obstet Gynaecol. 2012;52:106–12.\nKim JY, Song YG, Kim C-W, Lee MO. Uterine artery embolization using gelatin sponge particles for symptomatic focal and diffuse adenomyosis. Clin Exp Obstet Gynecol. 2021;48:59.\nLee MS, Kim MD, Lee M, Won JY, Park SI, Lee DY, K-hun L. Contrast-enhanced MR angiography of uterine arteries for the prediction of ovarian artery embolization in 349 patients. J Vasc Interv Radiol. 2012;23:1174–9.\nPark Y, Kim MD, Jung DC, Lee SJ, Kim G, Park SI, Won JY, Lee DY. Can measurement of apparent diffusion coefficient before treatment predict the response to uterine artery embolization for adenomyosis? Eur Radiol. 2014;25:1303–9.\nZheng R, Zeng D, Wan T-T, Guo W-B, Guo Y, Liu M-J. Predisposing factors for predicting the therapeutic response of adenomyosis after uterine artery embolization: Serum CA125 levels and accompanying endometriosis. Diagn Interv Radiol. 2018;24:364–71.\nPereira K, Morel-Ovalle LM, Wiemken TL, Kazmi S, Rode S, Hardy A, Vaheesan K. Intraprocedural superior hypogastric nerve block allows same-day discharge following uterine artery embolization. J Vasc Interv Radiol. 2020;31:388–92.\nYoon J, Valenti D, Muchantef K, Cabrera T, Toonsi F, Torres C, Bessissow A, Bandegi P, Boucher L-M. Superior hypogastric nerve block as post–uterine artery embolization analgesia: A randomized and double-blind clinical trial. Radiology. 2019;292:269–269.\nPereira K, Morel-Ovalle LM, Taghipour M, Sherwani A, Parikh R, Kao J, Vaheesan K. Superior hypogastric nerve block (SHNB) for pain control after uterine fibroid embolization (UFE): Technique and troubleshooting. CVIR Endovascular. 2020. https://doi.org/10.1186/s42155-020-00141-2.\nPark PJ, Kokabi N, Nadendla P, Lindsey T, Dariushnia SR. Efficacy of intraprocedural superior hypogastric nerve block in reduction of postuterine artery embolization narcotic analgesia use. Can Assoc Radiol J. 2020;71:75–80.\nDuvnjak S, Andersen PE. Intra-arterial lidocaine administration during uterine fibroid embolization to reduce the immediate postoperative pain: A prospective randomized study. CVIR Endovascular. 2020. https://doi.org/10.1186/s42155-020-0099-4.\nStratil P, Mizones H, Spencer E. Clinical and periprocedural pain management for uterine artery embolization. Semin Interv Radiol. 2013;30:354–63.\nLiang E, Brown B, Rachinsky M. A clinical audit on the efficacy and safety of uterine artery embolisation for symptomatic adenomyosis: Results in 117 women. Aust N Z J Obstet Gynaecol. 2018;58:454–9.\nAuthor information\nAuthors and Affiliations\nCorresponding author\nEthics declarations\nConflict of Interest\nThe authors declare that they have no conflict of interest.\nHuman and Animal Rights and Informed Consent\nThis article does not contain any studies with human or animal subjects performed by any of the authors.\nAdditional information\nPublisher's Note\nSpringer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.\nRights and permissions\nSpringer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.\nAbout this article\nCite this article\nRoop, S., Patel, S., Zhang, M. et al. Uterine Artery Embolization for Adenomyosis: A Review of Imaging, Techniques, Complications and Outcomes. Curr Obstet Gynecol Rep 12, 186–197 (2023). https://doi.org/10.1007/s13669-023-00367-6\nAccepted:\nPublished:\nVersion of record:\nIssue date:\nDOI: https://doi.org/10.1007/s13669-023-00367-6","source_license":"CC0","license_restricted":false}